Get started
NovoCure LimitedNovoCure LimitedNovoCure Limited

NovoCure Limited

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NVCR chart


Full chart

NVCR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.30 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.39 USD
Net income (FY)
‪−207.04 M‬ USD
Revenue (FY)
‪509.34 M‬ USD
Shares float
‪97.35 M‬
Beta (1Y)
2.03

Employees


Employees (FY)
‪1.45 K‬
Change (1Y)
+133 +10.08%
Revenue / Employee (1Y)
‪350.54 K‬ USD
Net income / Employee (1Y)
‪−142.49 K‬ USD

About NovoCure Limited


Sector
Health Technology
Industry
Medical Specialties
CEO
Asaf Danziger
Website
novocure.com
Headquarters
St. Helier
Founded
2000
ISIN
JE00BYSS4X48
FIGI
BBG009XW8PY2
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NVCR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NVCR highest yielding bonds


NVCR5301073
NovoCure Limited 0.0% 01-NOV-2025
Yield to maturity
5.62%
Maturity date
Nov 1, 2025

Explore more bonds 

Frequently Asked Questions


The current price of NVCR is 30.97 USD — it has increased by 1.57% in the past 24 hours. Watch NovoCure Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NovoCure Limited stocks are traded under the ticker NVCR.
NVCR stock has fallen by −2.49% compared to the previous week, the month change is a 80.06% rise, over the last year NovoCure Limited has showed a 130.60% increase.
We've gathered analysts' opinions on NovoCure Limited future price: according to them, NVCR price has a max estimate of 42.00 USD and a min estimate of 29.00 USD. Watch NVCR chart and read a more detailed NovoCure Limited stock forecast: see what analysts think of NovoCure Limited and suggest that you do with its stocks.
NVCR reached its all-time high on Jun 24, 2021 with the price of 232.76 USD, and its all-time low was 5.95 USD and was reached on Oct 31, 2016. View more price dynamics on NVCR chart.
See other stocks reaching their highest and lowest prices.
NVCR stock is 4.03% volatile and has beta coefficient of 2.03. Track NovoCure Limited stock price on the chart and check out the list of the most volatile stocks — is NovoCure Limited there?
Today NovoCure Limited has the market capitalization of ‪3.30 B‬, it has increased by 3.10% over the last week.
Yes, you can track NovoCure Limited financials in yearly and quarterly reports right on TradingView.
NovoCure Limited is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
NVCR earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.33 USD resulting in a 16.12% surprise. The estimated earnings for the next quarter are −0.36 USD per share. See more details about NovoCure Limited earnings.
NovoCure Limited revenue for the last quarter amounts to ‪155.09 M‬ USD, despite the estimated figure of ‪143.95 M‬ USD. In the next quarter, revenue is expected to reach ‪153.05 M‬ USD.
NVCR net income for the last quarter is ‪−30.57 M‬ USD, while the quarter before that showed ‪−33.38 M‬ USD of net income which accounts for 8.40% change. Track more NovoCure Limited financial stats to get the full picture.
No, NVCR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has ‪1.45 K‬ employees. See our rating of the largest employees — is NovoCure Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NovoCure Limited EBITDA is ‪−139.34 M‬ USD, and current EBITDA margin is −42.25%. See more stats in NovoCure Limited financial statements.
Like other stocks, NVCR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NovoCure Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NovoCure Limited technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NovoCure Limited stock shows the neutral signal. See more of NovoCure Limited technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.